{"analyses":[{"ciLowerLimit":"0.516","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.858","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0017","paramType":"Cox Proportional Hazard","paramValue":"0.665","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.7","upperLimit":"7.9","value":"7.4"},{"groupId":"OG001","lowerLimit":"5.5","upperLimit":"6.7","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"description":"The primary efficacy endpoint is invPFS for the Treatment Part of the study. The time to invPFS is calculated in months as the time from randomization to disease progression +1 day, as determined by RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) criteria or death due to any cause, whichever occurs first. Progression is defined using RECIST v1.1, as at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients randomized to the rucaparib arm.","id":"OG000","title":"Rucaparib"},{"description":"Patients randomized to the chemotherapy arm.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat (ITT) Population - All randomized patients in the treatment part of study.","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from C1D1 until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.","title":"Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (ITT Population)","type":"PRIMARY","unitOfMeasure":"Months"}